Viread Drug Patent Profile
✉ Email this page to a colleague
When do Viread patents expire, and what generic alternatives are available?
Viread is a drug marketed by Gilead Sciences Inc and is included in two NDAs.
The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viread
A generic version of Viread was approved as tenofovir disoproxil fumarate by TEVA PHARMS USA on March 18th, 2015.
Summary for Viread
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 89 |
Clinical Trials: | 91 |
Patent Applications: | 4,317 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for Viread |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for Viread |
What excipients (inactive ingredients) are in Viread? | Viread excipients list |
DailyMed Link: | Viread at DailyMed |
Recent Clinical Trials for Viread
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Albert Einstein College of Medicine | Phase 4 |
Université Protestant au Congo | Phase 4 |
Doris Duke Charitable Foundation | Phase 4 |
Pharmacology for Viread
Anatomical Therapeutic Chemical (ATC) Classes for Viread
Paragraph IV (Patent) Challenges for VIREAD
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIREAD | Tablets | tenofovir disoproxil fumarate | 150 mg, 200 mg, and 250 mg | 021356 | 1 | 2012-05-17 |
VIREAD | Tablets | tenofovir disoproxil fumarate | 300 mg | 021356 | 1 | 2010-01-26 |
US Patents and Regulatory Information for Viread
Expired US Patents for Viread
International Patents for Viread
See the table below for patents covering Viread around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2008120820 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOG | ⤷ Try a Trial |
Germany | 122008000033 | ⤷ Try a Trial | |
Portugal | 915894 | ⤷ Try a Trial | |
European Patent Office | 0206459 | 9-(PHOSPHONYLMETHOXYALKYL) ADENINES, METHOD FOR THEIR PREPARATION AND THEIR USE | ⤷ Try a Trial |
Brazil | 9811045 | ⤷ Try a Trial | |
Germany | 69324923 | ⤷ Try a Trial | |
Spain | 2131116 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for Viread
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0915894 | 91433 | Luxembourg | ⤷ Try a Trial | 91433, EXPIRES: 20220725 |
1301519 | CA 2016 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
1663240 | 300850 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN: -RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE; EN -TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623 |
1663240 | 60/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
1632232 | 122016000111 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
1663240 | PA2015038 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128 |
0582455 | SPC/GB08/022 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF EFAVIRENZ, EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, AND TENOFOVIR OR A PHARMACEUTICALLY ACCEPTABLE PRODRUG, SALT OR ESTER THEREOF, PARTICULARLY TENOFOVIR DISOPROXIL, ESPECIALLY TENOFOVIR DISOPROXIL FUMARATE; REGISTERED: UK EU/1/07/430/001 20071213 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |